Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SOMAR Corporation (8152.T)
Tokyo, JP
SOMAR Corporation, established in 1948 and headquartered in Tokyo, Japan, operates a diverse business portfolio encompassing materials, resins, environmental solutions, and food products, serving both domestic and international markets. The company provides specialized materials for various industries, including essential items for circuit boards like process films, board mounting adhesives, and substrate formation materials. Its offerings for electrical and electronic components feature magnetic materials, heat-resistant solvent-soluble polyimides, performance films, and protective exterior coatings. SOMAR also supplies light-shielding films for optical equipment and a range of magnetic, insulating, adhesive sealing, and light sheet materials specifically for automotive electrical components. Furthermore, the company develops a suite of products for paper chemicals, including inkjet output films for design and reproduction, alongside various additives such as slime control agents, antiseptic and antifungal agents, fluidity modifiers, binders, flocculants, and microbial carriers. It also provides sterilization, antiseptic, and antifungal agents for broader environmental applications. In the food sector, SOMAR manufactures thickening stabilizers, dried vegetables, and spices. Additionally, it offers cell culture products for the bio-field and skincare and hydrogen inhaler products for health and beauty. The company operated as Marusho Industrial Co., Ltd. until its rebranding to SOMAR Corporation in 1984.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.47% | -5.11% | -11.80% | -0.55% | -9.12% | +1.70% | +174.21% | +202.25% | +180.21% | +110.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+2.8% Q1'26: +7.3% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%-42.4% Q1'26: -82.9% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+4.4% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.4% Q1'26: +7.9% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+9.3% ★ Q1'26: +8.8% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.95× ★ Q1'26: 1.98× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Futoshi Sotani | President & Representative Director | — | male |
| Masaki Kobayashi | GM of the Business Division & Director | — | — |
| Seiji Ushio | GM of Sales Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8152.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
